NCT04817540招募中2 期
Phase II Trial of Anti-HER2 Treatment in HER2-enriched Early Breast Cancer Identified by PAM50 (HER2E-PAM, PAMILIA Study)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 59
- 试验地点
- 1
- 主要终点
- pathologic complete response rate (%, ypT0/isN0)
研究概览
简要总结
In this study, we prospectively analyzed molecular subtyping through the PAM 50 test in HER2-negative (IHC1+ or 2+ (FISH/SISH-)) breast cancer patients. A phase 2 single arm study was designed to determine whether the addition of HER2-targeted treatment with treatment increases the pathologic remission rate.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pathologically and cytologically documented unsectable/metastatic breast cancer that :
- •A. has confirmed HER2 negative expression regardless hormone receptor status
- •definition of HER2 negative breast cancer i) HER2 IHC 1+ without ISH or ii) HER2 IHC 2+ and ISH negative (average HER2 gene copy number <4 signals/cell in single probe ISH or HER2/CEP17 ratio <2.0 & average HER2 gene copy number <4 signals cell in dual-probe ISH)
- •No prior treatment of stage II-III breast cancer
- •HR+ & HER2- breast cancer : cT1-4N1-3
- •HR- & HER2- breast cancer : cT1N1-3 or cT2-4N0-3
- •No systemic metastasis confirmed by pathological or radiological evaluation
- •Patients over 19 years
- •Confirmed to HER2-enriched subtype by PAM50 study
- •Available FFPE 15-20 slides for evaluating PAM50 study
- •Adequate bone marrow functions i) Hemoglobin≥ 9g/dL ii) ANC ≥1,500/mm3 iii) Platelet ≥100,000/mm3
- •Adequate renal functions i) creatinine : ≤ 1.5 x UNL or ii) creatinine clearance (Ccr) ≥ 50 ml/min by Cockroft formula
- •Adequate liver functions i) Bilirubine : ≤ 1.5 x UNL ii) AST/ALT : ≤ 2.5 x UNL
- •Adequate cardiac functions
- •LVEF ≥50% (with MUGA scan or TTE)
- •Females of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to first dose of study treatment.
排除标准
- •History of previous treatments of ipsilateral or contralateral invasive breast cancer 2) Confirmation of systemic distant metastasis of breast cancer 3) History of other malignancy within the last 5 years, except curatively treated basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, less than 2cm of thyroid cancer (papillary, follicular, medullary).
- •inflammatory breast cancer (cT4d) 5) bilateral breast cancer(except, multifocal or multicentric breast cancer) 6) occult breast cancer 7) History of positivity for hepatitis B surface antigen, hepatitis C virus, or human immunodeficiency virus (HIV) 8) Woman of childbearing potential who is not consenting to use highly effective methods of birth control (eg, true abstinence [periodic abstinence (eg calendar ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception], sterilization, or other non-hormonal forms of contraception) during treatment 9) Uncontrolled infections and other serious diseases or medical conditions 10) Uncontrolled hyeprtension or clinically active cardiovascular disease: for example, cerebrovascular accident or transient isschemic attack, unstable angina, myocaridal infarction within 6 months prior to enrolment. Have symptomatic congestive heart failure (CHF; New York Heart Association II-IV) or symptomatic or poorly controlled cardiac arrhythmia.
- •Have any condition (eg, psychological, geographical, or medical) that does not permit compliance with the study and follow-up procedures or suggest that the patient is, in the investigator's opinion, not an appropriate candidate for the study 12) Patients who are hypesenstivie reaction to experimental drugs (doxorubicin, cyclophosphamide, paclitaxel, docetaxel, herzuma) 13) Peripheral neuropathy CTCAE v4.03 ≥ grade 2
研究组 & 干预措施
Single arm, Herzuma arm
Experimental
干预措施: Herzuma (Drug)
结局指标
主要结局
pathologic complete response rate (%, ypT0/isN0)
时间窗: 12 weeks
TPathologic Complete Response (pCR) rate, assessed as no evidence of invasive disease in excised surgical specimens of breast and/or axilla(ypT0/isYpN0), in participants who received at least 1 cycle of herzuma and taxane in HER2-enriched subtype breast cancer
次要结局
未报告次要终点
研究者
Joon Jeong
Professor
Gangnam Severance Hospital
研究点 (1)
Loading locations...
相似试验
尚未招募
不适用
Efficacy analysis of anti-HER2 treatment in HER2-enriched early breast cancer identified by PAM50KCT0006154Yonsei University Health System, Gangnam Severance Hospital59
撤回
2 期
Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast CancerTriple Negative Breast CancerBreast CancerNCT03872505Cedars-Sinai Medical Center
Unknown
2 期
Trastuzumab Biosimilar (Samfenet®) Plus Treatment of Physician's Choice (TPC) in Patients With HER2-positive Solid TumorHER-2 Protein OverexpressionHER-2 Gene AmplificationNCT04215159Jin-Hee Ahn42
已完成
不适用
A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in ChinaGastroesophageal Junction CancerGastric CancerNCT06585501Daiichi Sankyo805
招募中
不适用
A study for assessment of HER2 status using Gene-Protein Assay (GPA) in metastatic colorectal cancercolorectal cancerJPRN-UMIN000039751ational Cancer Center150